Adlai Nortye Biopharma Co., Ltd.

Building 8, No. 1008, Xiangwang Street, Cangqian Sub-District, Hangzhou, Zhejiang, China

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

90.0%

Phase 3

10.0%

Trial Status Distribution

Active, not recruiting

10.0%

Completed

40.0%

Not yet recruiting

10.0%

Recruiting

30.0%

Suspended

10.0%

Clinical Trials

Trials sponsored by this organization (10)

A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

Phase 1

Not yet recruiting

interventional

Sep 2026228 participants

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Phase 1

Recruiting

interventional

Jan 2026118 participants

An Initial Evaluation of AN8025 in Solid Tumors

Phase 1

Recruiting

interventional

Nov 202591 participants

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Phase 1

Suspended

interventional

Jan 202232 participants

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Phase 1

Completed

interventional

Oct 202115 participants

First in Human, Dose Escalation Study of AN4005

Phase 1

Recruiting

interventional

Sep 202131 participants

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Phase 1

Completed

interventional

Sep 202147 participants

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Phase 3

Completed

interventional

Dec 2020487 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations